Subcutaneous infliximab cut-off points in patients with inflammatory bowel disease. Data from the ENEIDA registry.

Marisa IborraBerta CaballolAlejandro GarridoJosé María HuguetFrancisco Mesonero GismeroÁngel PonferradaLara Arias GarcíaMarta Maia Boscá WattsSamuel J Fernández PradaEduard Brunet MasAna Gutiérrez CasbasElena CerrilloIngrid OrdásLucía RuizIrene García de la FiliaJaime Escobar OrtizBeatriz SiciliaElena RicartEugeni DomènechPilar Nos

Published in: Journal of Crohn's & colitis (2024)

Switching from IV-IFX to SC-IFX safely maintains long-term remission in patients with CD and UC. In maintenance, the optimal cut-off point associated with remission was 12-13 μg/mL.

Keyphrases

patients with inflammatory bowel disease
ulcerative colitis
disease activity
electronic health record
rheumatoid arthritis
systemic lupus erythematosus
big data
nk cells
data analysis
deep learning